- Eupraxia Pharmaceuticals (EPRX, Financial) is set to showcase its latest research at key investor and scientific conferences in April and May 2025.
- The company will present findings on EP-104IAR for knee osteoarthritis and EP-104GI for eosinophilic esophagitis.
- CEO Dr. James Helliwell and other key figures will provide insights into the company's innovations and strategies.
Eupraxia Pharmaceuticals (EPRX), a clinical-stage biotechnology company, has announced its participation in several significant conferences in April and May 2025. The company will present advancements in its product candidates, notably EP-104IAR for knee osteoarthritis and EP-104GI for eosinophilic esophagitis (EoE).
At the upcoming Osteoarthritis Research Society International (OARSI) World Congress in South Korea, Dr. Phil Conaghan will present research findings on the extended-release intra-articular injection EP-104IAR, emphasizing its sustained pain response for knee osteoarthritis patients. This presentation is scheduled for April 25-26, 2025.
During the Digestive Disease Week (DDW) in San Diego, scheduled for May 3-6, 2025, Dr. Evan Dellon will unveil results from the ongoing Phase 1b/2a study of EP-104GI for EoE, alongside Dr. Amanda Malone, who will discuss the epidemiology of esophageal strictures. These presentations will occur on May 3, 2025.
Additionally, Eupraxia's CEO, Dr. James Helliwell, will present at the Bloom Burton & Co. Healthcare Investor Conference in Toronto on May 5, 2025, providing insights into the company's strategic developments and clinical advancements. Moreover, Dr. Arjan Bredenoord will participate at the ESDE Annual Congress in Amsterdam from May 11-13, 2025, discussing Eupraxia's innovative approaches to treating esophageal disorders.
Further details and access to the presentations will be available on Eupraxia's official website, enhancing transparency and engagement with stakeholders and investors.
